Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

OTLK

Outlook Therapeutics Inc

Nov 14 • 04:00PM ET

1.57

+0.10 6.80 %

Healthcare • Biotechnology • USA • NASD

Peers: EYPT OCUL AKBA FGEN ALDX EDIT ADMA CLSD KALA NBIX

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.09	Insider Own	34.52%	Shs Outstand	43.48M	Perf Week	31.93%
Market Cap	69.74M	Forward P/E	-	EPS next Y	-1.00	Insider Trans	0.00%	Shs Float	29.09M	Perf Month	17.16%
Enterprise Value	95.54M	PEG	-	EPS next Q	-0.26	Inst Own	12.57%	Short Float	8.24%	Perf Quarter	-43.32%
Income	-43.44M	P/S	46.19	EPS this Y	55.71%	Inst Trans	-5.16%	Short Ratio	0.54	Perf Half Y	-10.29%
Sales	1.51M	P/B	-	EPS next Y	44.27%	ROA	-125.04%	Short Interest	2.40M	Perf YTD	-16.93%
Book/sh	-0.86	P/C	7.84	EPS next 5Y	49.92%	ROE	-	52W High	6.05 -74.07%	Perf Year	-74.96%
Cash/sh	0.20	P/FCF	-	EPS past 3/5Y	16.44% 36.59%	ROIC	-	52W Low	0.79 98.73%	Perf 3Y	-92.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	63.07%	Volatility	13.17% 8.65%	Perf 5Y	-90.35%
Dividend TTM	-	EV/Sales	63.27	EPS Y/Y TTM	86.28%	Oper. Margin	-4824.52%	ATR (14)	0.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.54	Sales Y/Y TTM	-	Profit Margin	-2885.82%	RSI (14)	65.63	Recom	2.20
Dividend Gr. 3/5Y	- -	Current Ratio	0.67	EPS Q/Q	38.38%	SMA20	19.30%	Beta	0.18	Target Price	6.25
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	32.16%	Rel Volume	1.75	Prev Close	1.47
Employees	23	LT Debt/Eq	-	Earnings	Aug 14 BMO	SMA200	-0.64%	Avg Volume	4.45M	Price	1.57
IPO	Jun 14, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	-24.82% 0.33%	Trades		Volume	7,787,469	Change	6.80%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-28-25	Downgrade	Guggenheim	Buy → Neutral
Dec-02-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Mar-27-24	Upgrade	BTIG Research	Neutral → Buy	$50
Feb-15-24	Upgrade	Chardan Capital Markets	Neutral → Buy	$3
Jan-25-24	Upgrade	Guggenheim	Neutral → Buy
Dec-27-23	Upgrade	CapitalOne	Equal Weight → Overweight	$5
Aug-31-23	Downgrade	H.C. Wainwright	Buy → Neutral	$5 → $1
Aug-31-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-30-23	Downgrade	Guggenheim	Buy → Neutral
Aug-30-23	Downgrade	CapitalOne	Overweight → Equal Weight
Aug-30-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$4.50 → $1
Aug-30-23	Downgrade	BTIG Research	Buy → Neutral
Jul-13-23	Initiated	CapitalOne	Overweight	$5
Apr-03-23	Initiated	Guggenheim	Buy	$5
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight	$4
Oct-31-22	Initiated	BTIG Research	Buy	$7
Sep-13-22	Initiated	Chardan Capital Markets	Buy	$10
Sep-11-19	Initiated	Ladenburg Thalmann	Buy	$9
May-16-19	Initiated	Oppenheimer	Outperform	$12

Show Previous Ratings

Nov-13-25 08:30AM	Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) +14.84%
Nov-03-25 08:35AM	Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 (GlobeNewswire)
Sep-29-25 08:45AM	Outlook Therapeutics Provides Update on Type A Meeting with FDA (GlobeNewswire) +9.27%
Sep-03-25 08:35AM	Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) (GlobeNewswire)
Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:35AM	Loading…
08:35AM	Outlook Therapeutics Requests Type A Meeting with FDA (GlobeNewswire)
Aug-29-25 10:38AM	OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug (Zacks) -21.91%
09:38AM	Marvell downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
Aug-28-25 11:15AM	FDA Rejects Outlook Therapeutics Eye Drug For Second Time (Benzinga) -54.11%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
06:30AM	Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD (GlobeNewswire)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +18.38%
Aug-14-25 09:15AM	Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +14.08%
08:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Jul-30-25 05:50AM	New Strong Buy Stocks for July 30th (Zacks)
09:00AM	Loading…
Jul-24-25 09:00AM	Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase (GlobeNewswire)
Jul-22-25 08:45AM	Outlook Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-01-25 08:05AM	Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer (GlobeNewswire)
Jun-18-25 09:05AM	Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event (GlobeNewswire)
Jun-11-25 05:06AM	Outlooks wet AMD treatment accepted by SMC for NHS Scotland (Pharmaceutical Technology)
Jun-10-25 08:05AM	Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire)
Jun-02-25 07:00AM	Outlook Therapeutics Announces Commercial Launch of LYTENAVA (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD (GlobeNewswire)
May-23-25 06:30AM	Outlook Therapeutics Announces Pricing of $13.0 Million Public Offering (GlobeNewswire)
May-22-25 04:01PM	Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
May-15-25 04:01PM	Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Apr-08-25 08:45AM	Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire)
Mar-20-25 05:24PM	Outlook Therapeutics files to sell 21.72M shares of common stock for holders (SeekingAlpha)
Feb-28-25 08:05AM	Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration (GlobeNewswire) +8.70%
Feb-19-25 09:00AM	Outlook Therapeutics Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
08:05AM	Loading…
Feb-14-25 08:05AM	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Feb-04-25 09:05AM	Outlook Therapeutics Participates in Virtual Investor What This Means Segment (GlobeNewswire)
Jan-31-25 08:05AM	Outlook Therapeutics Appoints Faisal G. Sukhtian as Chairman of the Board of Directors (GlobeNewswire)
Jan-23-25 09:05AM	Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD (GlobeNewswire)
Jan-22-25 09:05AM	Outlook Therapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (GlobeNewswire) -8.93%
Jan-16-25 12:09PM	Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug (Benzinga)
06:00AM	Outlook Therapeutics Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial (GlobeNewswire)
Jan-08-25 09:15AM	Outlook Therapeutics Participates in Virtual Investor What This Means Segment (GlobeNewswire) -5.22%
Dec-30-24 07:45AM	Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss (GuruFocus.com) -7.46%
Dec-28-24 10:50PM	Outlook Therapeutics Reports 2024 Financial Results (TipRanks)
08:10AM	Outlook Therapeutics provides ONS-5010/LYTENAVA update (TipRanks)
Dec-27-24 08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire) +18.24%
Dec-13-24 04:30PM	Outlook Therapeutics Streamlines Operations (GlobeNewswire)
Dec-04-24 08:05AM	Outlook Therapeutics Announces NICE Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire) -8.03%
Dec-03-24 04:30PM	Outlook Therapeutics Announces Executive Leadership Transition (GlobeNewswire) -11.08%
Nov-30-24 05:50AM	Outlook Therapeutics price target lowered to $9 from $50 at BTIG (TipRanks)
Nov-27-24 11:08AM	Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial (Pharmaceutical Technology) -65.24%
11:07AM	Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial (Clinical Trials Arena)
09:27AM	Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? (Benzinga)
06:50AM	Outlook Therapeutics Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial (GlobeNewswire)
Nov-06-24 08:05AM	Outlook Therapeutics to Present at the Guggenheim Healthcare Innovation Conference (GlobeNewswire)
Oct-17-24 09:00AM	Outlook Therapeutics Participates in a Virtual Investor CEO Connect Segment (GlobeNewswire)
Sep-16-24 08:05AM	Outlook Therapeutics to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire) -8.35%
Sep-13-24 09:05AM	Outlook Therapeutics Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series (GlobeNewswire)
Sep-04-24 08:35AM	Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial (GlobeNewswire) +9.12%
Sep-03-24 08:45AM	Outlook Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -8.30%
Aug-15-24 06:20AM	Q3 2024 Outlook Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-24 07:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire) -5.29%
Aug-12-24 09:05AM	Outlook Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-09-24 07:16AM	Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now? (Insider Monkey)
Aug-07-24 08:35AM	Outlook Therapeutics to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast (GlobeNewswire)
Jul-30-24 09:10AM	Outlook Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2024 (GlobeNewswire)
Jul-08-24 08:35AM	Outlook Therapeutics Announces UK MHRA Marketing Authorization of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire) +7.38%
Jun-25-24 07:30AM	3 Undervalued Gems Set to Soar 1,000% by 2026 (InvestorPlace)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-12-24 10:00AM	Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series (ACCESSWIRE)
Jun-11-24 09:05AM	Outlook Therapeutics to Present at the Virtual Investor Pitch Conference (GlobeNewswire) +7.92%
Jun-10-24 08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
Jun-06-24 10:30AM	Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor 'What This Means' Segment Hosted by JTC Team (ACCESSWIRE)
May-28-24 08:05AM	Outlook Therapeutics Receives European Commission Marketing Authorization for LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire)
May-17-24 04:27AM	Q2 2024 Outlook Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +6.14%
May-15-24 10:53PM	OTLK Stock Earnings: Outlook Therapeutics Misses EPS for Q2 2024 (InvestorPlace)
05:00PM	Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire)
May-13-24 11:18AM	Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK (MT Newswires)
08:50AM	Outlook Therapeutics Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire)
May-09-24 08:45AM	Outlook Therapeutics to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast (GlobeNewswire)
May-02-24 09:05AM	Outlook Therapeutics to Present at the Retina World Congress 2024 (GlobeNewswire)
Apr-29-24 09:00AM	Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase (GlobeNewswire) +7.95%
Apr-26-24 06:37AM	Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-15-24 04:15PM	Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million (GlobeNewswire)
12:54PM	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential (InvestorPlace)
Apr-10-24 03:30PM	Insiders are Piling into These 10 Healthcare Stocks in 2024 (Insider Monkey)
Mar-22-24 07:35AM	Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) +22.59%
Mar-18-24 05:10PM	Outlook Therapeutics Announces Closing of Private Placement of up to $159 Million (GlobeNewswire) -5.52%
Mar-12-24 08:05AM	Outlook Therapeutics Announces Effective Date for 1-for-20 Reverse Stock Split (GlobeNewswire) -10.57%
Mar-06-24 03:36PM	7 of the Best Speculative Stocks You Can Snag for Less Than $1 (InvestorPlace)
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
Feb-14-24 05:27PM	Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments (GuruFocus.com) +5.08% +15.35%
08:05AM	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire)
Jan-31-24 08:05AM	Outlook Therapeutics Doses First Subject in NORSE EIGHT (GlobeNewswire) -6.99%
Jan-24-24 08:06AM	Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study (Zacks) -9.87%
Jan-23-24 08:00AM	Outlook Therapeutics Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010 (GlobeNewswire) +30.53%
Jan-02-24 10:18PM	Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire) +6.08%
Dec-27-23 02:03PM	OTLK Stock Earnings: Outlook Therapeutics Reported Results for Q4 2023 (InvestorPlace)
09:30AM	OUTLOOK SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Dec-26-23 02:15PM	January 2. 2024 Lawsuit Deadline: Investors who lost over $200,000 with Outlook Therapeutics, Inc. (NASDAQ: OTLK) shares should contact the Shareholders Foundation (GlobeNewswire) +5.41%
Dec-22-23 08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU (GlobeNewswire)
Dec-19-23 08:05AM	Outlook Therapeutics Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010 (GlobeNewswire) +9.73%
Dec-06-23 08:05AM	Outlook Therapeutics Announces Strategic Organizational Realignment (GlobeNewswire)
Nov-27-23 08:05AM	Outlook Therapeutics Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010 (GlobeNewswire)

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OTLK

Outlook Therapeutics Inc

Upgrade your FINVIZ experience